Piramal Pharma Limited’s Pharma Solutions (PPS) business, a Contract Research, Development and Manufacturing Organization (CDMO), has made a multi-million dollar investment to create a world-class high-throughput screening facility that will augment existing in vitro biology capabilities at its drug discovery services site in Ahmedabad, India. The expansion, which is expected to go live in 3Q22, will significantly add to the primary and secondary screening capabilities of compounds prepared at the site.
 
The benefits of this new investment include integrated chemistry and biology services from a single site, with anticipated significant improvements to drug discovery cycle times. New personnel with experience in biology services are also being added to the site team.
 
The new high-throughput screening technology enables PPS to evaluate and screen 1000 compounds per week using various assay platform technologies such as Fluorescent Imaging Plate Reader (FLIPR), TR-FRET/HTRF, Fluorescence Polarization (FP), absorbance, Luminescence/ Electrochemiluminescence (ECL), Alpha Screen, Lantha Screen, Flow Cytometry, and high content imaging. These platforms will be applicable to a variety of targets (e.g., G-protein-coupled receptors (GPCRs) and kinase-targeted therapies). 
 
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “Assisting customers in the discovery process is synergistic with our efforts to be a patient-centric CDMO. With this investment, we are enhancing our discovery platform by adding new in vitro biology services to our existing capabilities, making us a more integrated partner.”